Patents Examined by Zachariah Lucas
  • Fully human influenza M2 specific antibodies
    Patent number: 8460670
    Abstract: The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for the expression of said anti-bodies. Furthermore, the invention relates to the use of said antibodies in the treatment and/or prevention of influenza A virus infection, preferably in humans.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: June 11, 2013
    Assignee: Intercell AG
    Inventors: Martin F. Bachmann, Monika Bauer, Roger Beerli, Nicole Schmitz
  • Polyvalent chimeric rubella virus-based vaccines
    Patent number: 8460680
    Abstract: A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: June 11, 2013
    Assignee: National Health Research Institutes
    Inventors: Yen-Hung Chow, Charles Dwo-Yuan Sia, Pele Choi-Sing Chong, Kuang-Nan Hsiao
  • Method of detection of microorganisms with enhanced bacteriophage amplification
    Patent number: 8455186
    Abstract: A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage exposed sample, and a substance which enhances bacteriophage amplification or sensitivity; providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to infect the microorganism; and assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: June 4, 2013
    Assignee: MicroPhage™ Incorporated
    Inventors: Jonathan Drew Smith, Jon C. Rees, Duane Bush, Breanna Leigh Dreiling, Maria Izzo, Breanna Christine Smith, Bernard Sportmann, Tiffany Steinmark, Richard Proctor
  • Bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus
    Patent number: 8440446
    Abstract: Novel bacteriophage strains are disclosed and their use in the production of preparations for use in the treatment of bacterial infections, particularly with drug resistant strains of bacteria of the genus Enterococcus, particularly those belonging to the species Enterococcus faecalis.
    Type: Grant
    Filed: September 27, 2009
    Date of Patent: May 14, 2013
    Assignee: Instytut Immunologii I Terapii Doswiadzalnej Pan
    Inventors: Beata Weber-Dabrowska, Andrzej Górski, Ryszard Miedzybrodzki
  • M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications
    Patent number: 8415131
    Abstract: Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: April 9, 2013
    Assignee: University of South Carolina
    Inventors: Qian Wang, Kai Li, Charlene Mello
  • Signaling peptides
    Patent number: 8415462
    Abstract: The present invention provides novel peptides of specified sequence and their use as a signal peptide or a membrane-anchoring peptide. It also relates to chimeric polypeptide comprising one or more such peptides and a polypeptide of interest as well as nucleic acid molecules, vectors, infections vital particles and host cells encoding such peptides and chimeric polypeptides. The present invention also relates to a pharmaceutical composition comprising such elements and a pharmaceutically acceptable vehicle. The present invention also provides a method for recumbently producing a polypeptide using such peptides, especially for directing expression of a polypeptide of interest extracellularly or anchored at the surface of the plasma membrane.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: April 9, 2013
    Assignee: Transgene S.A.
    Inventors: Nathalie Sylvestre, Eric Jacobs
  • Engineered scFv against bovine herpes virus type I
    Patent number: 8383115
    Abstract: The present disclosure describes a single chain variable fragment (scFv) that binds BHV-1 virus comprising a light chain variable region, a linker and a heavy chain variable region. The disclosure also describes nucleic acid molecules encoding the scFv molecules, methods and uses thereof for treating or neutralizing BHV-1 infection and diagnostic methods, agents and kits thereof.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: February 26, 2013
    Assignee: Azad Kumar Kaushik
    Inventors: Azad Kumar Kaushik, Madhuri Koti, Eva Nagy
  • Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof
    Patent number: 8377477
    Abstract: The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: (i) preparing said microparticles from at least one bioresorbable polymer without stabilizer and without surfactant, and (ii) bonding said protein substances to the microparticles obtained in step (i) without surfactant. It further relates to the bioresorbable microparticles thus obtained and use thereof in diagnosis and therapy.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: February 19, 2013
    Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Yasemin Ataman-Onal, Thierry Delair, Geneviève Inchauspe, Pascale Jeannin, Glaucia Paranhos-Baccala, Bernard Verrier
  • Purified antibody to the extracellular domain of NKp44L
    Patent number: 8372955
    Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 12, 2013
    Assignees: Assistance Publique Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Vincent Viellard, Patrice Debre
  • Chimeric HIV fusion proteins as vaccines
    Patent number: 8372407
    Abstract: A method for inducing HIV antigen-specific immune responses is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of a chimeric fusion protein comprising: (a) a first polypeptidyl region comprising a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain, located at the N-terminus of the fusion protein; and (b) a second polypeptidyl region with a fusion peptide of HIV gp120-C1-C5-gp41 with the amino acid sequence of SEQ ID NO: 7. A method for inducing neutralizing antibodies against HIV-1 is also disclosed.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 12, 2013
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Chao-Wei Liao, Hsiu-Kang Chang
  • Dendritic cell binding proteins and uses thereof
    Patent number: 8372409
    Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: February 12, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Mansour Mohamadzadeh
  • Modified vaccinia virus ankara for the vaccination of neonates
    Patent number: 8372622
    Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: February 12, 2013
    Assignee: Bavarian Nordic A/S
    Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
  • Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
    Patent number: 8361473
    Abstract: Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: January 29, 2013
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Oryan Makler, Yoram Reiter
  • Epinecidin-1 as a vaccine adjuvant for enhancing immune responses
    Patent number: 8361483
    Abstract: A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1 and the virus to a mammal, wherein the virus has envelope protein and is infectious to the mammal. A vaccine kit and a method for preventing Japanese encephalitis virus (JEV) infection are also disclosed.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: January 29, 2013
    Assignee: Academia Sinica
    Inventors: Jyh-Yih Chen, Chang-Jer Wu
  • Methods for treating lentivirus infections
    Patent number: 8338180
    Abstract: The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. The present invention provides agents identified by a subject screening method; and further provides methods for treating lentivirus infections.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: December 25, 2012
    Assignee: The J. David Gladstone Institutes
    Inventors: Warner C. Greene, Kimberly S. Stopak, Carlos M. C. deNoronha, Wesley M. Yonemoto
  • Anti-HIV immunogens and methods for inducing an immune response
    Patent number: 8338582
    Abstract: The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to a composition comprising said epitopes and the uses of said composition, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to anti-HIV-1 prophylactic vaccines and therapeutic vaccines. Furthermore, the present invention refers to a method for the identification of epitopes and methods for treating or preventing an infection caused by the HIV-1 virus.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: December 25, 2012
    Assignees: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Fundacao Zerbini, Universidade de Sao Paulo-USP
    Inventors: Edecio Cunha Neto, Jorge Elias Kalil Filho, Simone Goncalves Da Fonseca
  • Bionanomaterials and their synthesis
    Patent number: 8334127
    Abstract: The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: December 18, 2012
    Assignee: University of South Carolina
    Inventors: Qian Wang, Zhongwei Niu
  • Methods for diagnosis and monitoring of neurological disease by detection of an excephalotoxin
    Patent number: 8334100
    Abstract: Encephalotoxin produced by activated mononuclear phagocytes is present in individuals having neurological disease including neurodegenerative and neuro-inflammatory diseases, such as Alzheimer's disease (AD), HIV-1-associated dementia (HAD), Creutzfeldt-Jakob disease, Mild Cognitive Impairment, prion disease, minor cognitive/motor dysfunction, acute stroke, acute trauma, or neuro-AIDS. Biochemical detection of encephalotoxin according to the methods of the invention will allow diagnosis of neurological disease in early, presymptomatic stages, thereby allowing early intervention in disease progression as well as identification of subjects or populations at risk for developing neurodegenerative disease. The methods of the invention also provide a mechanism for monitoring progression and treatment of neurological disease.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: December 18, 2012
    Assignee: Jacobus Pharmaceutical Company, Inc.
    Inventor: Dana J. Giulian
  • Method for detecting and removing endotoxin
    Patent number: 8329393
    Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: December 11, 2012
    Assignee: Hyglos Invest GmbH
    Inventors: Stefan Miller, Roman Meyer, Renate Grassl, Manfred Biebl, Holger Grallert
  • bacteriophage and antibacterial composition comprising the same
    Patent number: 8329442
    Abstract: Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: December 11, 2012
    Assignee: CJ Cheiljedang Corporation
    Inventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi